A virus-based vaccine may prevent cervical cancer

Current Infectious Disease Reports

Volumn 7, Issue 2, 2005, Pages 125-131

  Gravitt, Patti E ^b   Shah, Keerti V ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CAPSID PROTEIN; PLACEBO; RECOMBINANT DNA; VIRUS PROTEIN; VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOOD INTAKE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH PROGRAM; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; INFECTION PREVENTION; MALE; PAPANICOLAOU TEST; PUBLIC HEALTH; RECOMBINANT DNA TECHNOLOGY; REVIEW; SEX DIFFERENCE; UTERINE CERVIX CANCER; VIRUS PARTICLE; WART VIRUS;

EID: 17044411344     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0072-3     Document Type: Review

References (40)

1. Pisani P, Parkin DM, Munoz N, Ferlay J: Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997, 6:387-400.
2. Huang K, Lin S: Nationwide vaccination: a sucess story in Taiwan. Vaccine 2000, 18(Suppl 1):S35-S38.
3. Kao JH, Chen DS: Global control of hepatitis B virus infection. Lancet Infect Dis 2002, 2:395-403.
4. Walboomers JMM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
5. Munoz N, Bosch FX, Sanjose S, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
6. Koutsky LA, Ault KA, Wheeler CM, et al.: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645-1651.
7. Lowy DR, Howley PM: Papillomaviruses. In Fields Virology. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wilkins; 2001:2231-2264.
8. Ho GY, Bierman R, Beardsley L, et al.: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428.
9. Franco EL, Villa LL, Sobrinho JP, et al.: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999, 180:1415-1423.
10. Galloway DA: Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003, 3:469-475.
11. Schiller JT, Lowy DR: Preventive human papillomavirus vaccines. In Cervical Cancer: From Etiology to Prevention. Edited by Rohan T, Shah KV. Dordrecht: Kluwer Academic Publisher; 2004:325-343.
12. Lowy DR, Frazer IH: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003, 31:111-116.
13. Shah KV, Howley PM: Papillomavirus. In Virology. Edited by Fields BN, Knipe DM, Howley PM, et al. Philadelphia: Lippincott-Raven; 1996:2077-2109.
14. Kirnbauer R, Booy F, Cheng N, et al.: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89: 2180-12184.
15. Hagensee ME, Yaegashi N, Galloway DA: Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993, 67:315-322.
16. Zhuo J, Stenzel DJ, Sun XY, Frazer IH: Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol 1993, 74:763-768.
17. Breitburd F, Kirnbauer R, Hubbert NL, et al.: Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69:3959-3963.
18. Christensen ND, Reed CA, Cladel NM, et al.: Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996, 70:960-965.
19. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al.: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995, 92:11553-11557.
20. Kirnbauer R, Chandrachud LM, O'Neil BW, et al.: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996, 219:37-44.
21. Harro CD, Pang YY, Roden RB, et al.: Safety and immunogenicity trial in adult volunteers of an HPV 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001, 93:284-292.
22. Harper DM, Franco EL, Wheeler C, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
23. Stone KM, Karem KL, Sternberg MR, et al.: Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002, 186:1396-1402.
24. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al.: Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003, 95:1128-1137.
25. Clifford GM, Smith JS, Plummer M, et al.: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73.
26. Roden RB, Yutzy WH, Fallon R, et al.: Minor capsid protein of human genital papillomavirus contains subdominant, cross-neutralizing epitopes. Virology 2000, 270:254-257.
27. Kawana K, Yasugi T, Kanda T, et al.: Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 2003, 21:4256-4260.
28. Pinto LA, Edwards J, Castle PE, et al.: Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003, 188:327-338.
29. Greenstone HL, Nieland JD, de Visser KE, et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A 1998, 95:1800-1805.
30. Liu XS, Liu WJ, Zhao KN, et al.: Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol 2002, 80: 1-29.
31. Muller M, Zhuo J, Reed TD, et al.: Chimeric papillomavirus-like particles. Virology 1997, 234:93-111.
32. Rose RC, Lane C, Wilson S, et al.: Oral vaccination of mice with human papillomavirus virus-like particles induces systematic virus-neutralizing antibodies. Vaccine 1999, 17:2129-2135.
33. Nardelli-Haefliger D, Roden RB, Benyacoub J, et al.: Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systematic neutralizing antibodies in mice. Infect Immun 1997, 65:3328-3336.
34. Biemelt S, Sonnewald U, Galmbacher P, et al.: Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003, 77:9211-9220.
35. Warzecha H, Mason HS, Lane C, et al.: Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003, 77:8702-8711.
36. Gillison ML, Koch WM, Capone RB, et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92: 09-720.
37. Goldie SJ, Kohli M, Grima D, et al.: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604-615.
38. Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290:781-789.
39. Goldie SJ, Grima D, Kohli M, et al.: A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003, 106:896-904.
40. Bosch FX, Manos MM, Munoz N, et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802.